{"id":56140,"date":"2026-02-03T16:21:41","date_gmt":"2026-02-03T08:21:41","guid":{"rendered":"https:\/\/flcube.com\/?p=56140"},"modified":"2026-04-10T23:39:44","modified_gmt":"2026-04-10T15:39:44","slug":"sanegenebio-partners-with-genentech-on-rnai-therapy-in-1-7b-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56140","title":{"rendered":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal"},"content":{"rendered":"\n<p><strong>SanegeneBio<\/strong>, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with <strong>Genentech<\/strong>, a member of the Roche Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX:\u202fROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS:\u202fRHHBY<\/a>), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an <strong>upfront payment of USD\u202f200\u202fmillion<\/strong> and is eligible for milestone payments up to <strong>USD\u202f1.5\u202fbillion<\/strong> , plus tiered royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>SanegeneBio (Platform Provider) \/ Genentech (Roche Group)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>RNAi therapy (preclinical)<\/td><\/tr><tr><td><strong>SanegeneBio Role<\/strong><\/td><td>Early\u2011stage research and development<\/td><\/tr><tr><td><strong>Genentech Role<\/strong><\/td><td>Clinical development and global commercialization<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f200\u202fmillion<\/td><\/tr><tr><td><strong>Milestone Potential<\/strong><\/td><td>Up to USD\u202f1.5\u202fbillion (development &amp; sales)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered on net sales<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary RNAi drug discovery with novel chemical modifications and delivery technologies<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Expands Genentech\u2019s RNAi pipeline; validates SanegeneBio\u2019s platform for breakthrough siRNA drugs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-innovation\">Technology Platform &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Proprietary Platform:<\/strong> SanegeneBio\u2019s RNAi platform encompasses novel chemical modifications and delivery technologies to develop <strong>potential breakthrough siRNA drugs<\/strong> across multiple disease areas<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Enhanced stability and targeted delivery address key limitations of first\u2011generation RNAi therapies<\/li>\n\n\n\n<li><strong>Pipeline Potential:<\/strong> Platform enables rapid development of candidates for oncology, cardiovascular, and rare genetic diseases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RNAi Therapeutics Market:<\/strong> Global market valued at <strong>$5\u202fbillion<\/strong> : in 2025, projected to exceed <strong>$15\u202fbillion<\/strong> : by 2030 driven by expanding indications and improved delivery<\/li>\n\n\n\n<li><strong>Revenue Synergies:<\/strong> $200\u202fM upfront provides immediate funding for platform expansion; $1.5\u202fB milestone potential positions SanegeneBio for sustained growth<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Deal with Genentech follows similar big\u2011pharma RNAi partnerships, confirming SanegeneBio as a leading China\u2011based RNAi discovery engine<\/li>\n\n\n\n<li><strong>Genentech\u2019s Portfolio:<\/strong> Strengthens Roche\u2019s position in genetic medicine, complementing its existing RNAi assets and antibody\u2011drug conjugate platforms<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> IND\u2011enabling studies expected to commence <strong>Q3\u202f2026<\/strong>; Genentech to assume full development leadership post\u2011preclinical<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, platform scalability, and revenue potential for SanegeneBio\u2019s RNAi partnership. Actual results may differ due to clinical development risks, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1111,940,64,163,1859,939],"class_list":["post-56140","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-genentech","tag-otcmkts-rhhby","tag-rnai-aso","tag-roche","tag-sanegenebio","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56140\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal\" \/>\n<meta property=\"og:description\" content=\"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56140\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T08:21:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:39:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal\",\"datePublished\":\"2026-02-03T08:21:41+00:00\",\"dateModified\":\"2026-04-10T15:39:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Genentech\",\"OTCMKTS: RHHBY\",\"RNAi \\\/ ASO\",\"Roche\",\"SanegeneBio\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56140#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56140\",\"name\":\"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-03T08:21:41+00:00\",\"dateModified\":\"2026-04-10T15:39:44+00:00\",\"description\":\"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56140\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56140#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal - Insight, China&#039;s Pharmaceutical Industry","description":"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56140","og_locale":"en_US","og_type":"article","og_title":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal","og_description":"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.","og_url":"https:\/\/flcube.com\/?p=56140","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T08:21:41+00:00","article_modified_time":"2026-04-10T15:39:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56140#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56140"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal","datePublished":"2026-02-03T08:21:41+00:00","dateModified":"2026-04-10T15:39:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56140"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Genentech","OTCMKTS: RHHBY","RNAi \/ ASO","Roche","SanegeneBio","SWX: ROP"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56140#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56140","url":"https:\/\/flcube.com\/?p=56140","name":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-03T08:21:41+00:00","dateModified":"2026-04-10T15:39:44+00:00","description":"SanegeneBio, a Suzhou\u2011based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a member of the Roche Group (SWX:\u202fROG, OTCMKTS:\u202fRHHBY), to advance an RNAi therapy based on SanegeneBio\u2019s proprietary discovery platform. Under the agreement, Genentech gains exclusive global rights to develop and commercialize the drug, while SanegeneBio will receive an upfront payment of USD\u202f200\u202fmillion and is eligible for milestone payments up to USD\u202f1.5\u202fbillion , plus tiered royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56140#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56140"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56140#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56140"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56140\/revisions"}],"predecessor-version":[{"id":56141,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56140\/revisions\/56141"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}